Here is what you’ll find in this week’s newsletter!

It’s only a 5 minute read, but it will make you 10x smarter.

DEEP DIVE 📚

For years, GLP-1 drugs occupied a narrow lane in Medicare — covered only when prescribed for type 2 diabetes, cardiovascular risk reduction, or sleep apnea.

Weight management? Off the table, thanks to a decades-old statutory prohibition on Part D coverage of weight loss drugs. That prohibition hasn't gone away, but CMS found a workaround.

On July 1, 2026, the Medicare GLP-1 Bridge launches as a centrally administered demonstration program that gives eligible beneficiaries access to GLP-1 drugs for weight management. With the launch days away, we break down the full operational picture.

—

On December 23, 2025, CMS announced a short-term demonstration — officially the Medicare GLP-1 Bridge — designed to expand access to certain weight-management GLP-1 drugs for Medicare Part D beneficiaries who are not eligible for coverage through their existing plan. The program launches July 1, 2026 and runs through December 31, 2027.

The structural headline: this program operates entirely outside the standard Part D benefit. Part D sponsors carry no risk, do not need to opt in, and the $50 copay does not count toward the beneficiary's true out-of-pocket costs (TrOOP) or deductible. It is administered through a single central processor — not plan-by-plan.

—

Eligibility is structured as an exclusion model — the GLP-1 Bridge is for Medicare beneficiaries who cannot get GLP-1 coverage through their Part D plan for weight management. Two key gates apply: plan type eligibility and clinical criteria.

A prescriber must attest via prior authorization that the beneficiary is at least 18 years old, is receiving the drug for weight reduction (not another approved indication), and meets one of the following BMI thresholds:

CMS requires the clinical criteria to be met at the time GLP-1 therapy was initiated — not at the time of the prior authorization request. This means a patient who had a BMI of 37 when they started a GLP-1 in 2024 and now has a BMI of 34 can still qualify. The prescriber attests to the BMI at initiation.

⚠️Key Disqualifier⚠️ - If a beneficiary has type 2 diabetes, moderate-to-severe sleep apnea (OSA), or non-cirrhotic MASH with moderate-to-advanced liver fibrosis, they are NOT eligible for the GLP-1 Bridge — their GLP-1 claim must go through the Part D plan instead. The same applies if the drug is being prescribed to reduce cardiovascular risk in beneficiaries with established CVD.

—

All three drugs must be prescribed specifically to reduce excess body weight and maintain weight reduction. Prescriptions for other approved indications do not qualify and must be handled through the Part D plan.

—

Beneficiaries will have a flat $50 copay for every fill, regardless of low-income subsidy (LIS) status. This copay does not count toward the Part D deductible, TrOOP, or Medicare Prescription Payment Plan. Manufacturer coupons and discount programs may not be applied.

The GLP-1 Bridge's net drug price is $245 per monthly supply, paid by CMS to the participating manufacturer. Pharmacies are reimbursed at the wholesale acquisition cost (WAC) of the drug, minus the $50 copay, plus a dispensing fee of $3 per claim (or $5 for long-term care residents), plus applicable sales tax.

—

CMS selected Humana, the current LI NET program administrator, to manage prior authorization, claims adjudication, and pharmacy payment for the GLP-1 Bridge. Claims are submitted electronically via the NCPDP Telecommunication Standard. Paper claims and direct member reimbursements are not accepted.

The GLP-1 Bridge is the primary payer and will not coordinate benefits with other payers. Because the program operates outside Part D, Part D sponsors are not involved in claims adjudication for GLP-1 Bridge-covered fills.

—

The July 1 launch is the beginning of the story, not the end. CMS has committed to sharing GLP-1 Bridge utilization data with Part D plan sponsors ahead of potential BALANCE Model integration — meaning the data generated over the next 18 months will directly shape how GLP-1 weight management coverage looks in Part D long-term. We will be watching the program closely and will provide updates as new operational guidance, utilization trends, and policy developments surface.

This one is worth following.

—

Sources: CMS Medicare GLP-1 Bridge program page; Medicare GLP-1 Bridge: Information for Pharmacies (June 2026); Medicare GLP-1 Bridge: Information for Prescribers (June 2026)

If you’re ready, here are some ways we can help you: